Xeris Biopharma Holdings, Inc. - PE Ratio

The PE Ratio as of June 2026 (TTM) for Xeris Biopharma Holdings, Inc. (XERS) is 99.29

According to Xeris Biopharma Holdings, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 99.29. This represents a change of -44.98% compared to the average of 180.48 of the last 4 quarters.

Xeris Biopharma Holdings, Inc. (XERS) Historical PE Ratio (quarterly & annually)

How has XERS PE Ratio performed in the past?

The mean historical PE Ratio of Xeris Biopharma Holdings, Inc. over the last ten years is 221.26. The current 99.29 PE Ratio has changed 4.39% with respect to the historical average. Over the past ten years (40 quarters), XERS's PE Ratio was at its highest in in the September 2025 quarter at 678.33. The PE Ratio was at its lowest in in the June 2025 quarter at -96.49.

Xeris Biopharma Holdings, Inc. (XERS) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Xeris Biopharma Holdings, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Xeris Biopharma Holdings, Inc. (XERS) Average PE Ratio

How has XERS PE Ratio performed in the past?

The current PE Ratio of Xeris Biopharma Holdings, Inc. (XERS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Xeris Biopharma Holdings, Inc. (XERS) PE Ratio vs. Peers

How is XERS’s PE Ratio compared to its peers?

Xeris Biopharma Holdings, Inc.’s PE Ratio is greater than Immunocore Holdings plc (-76.39), greater than Sionna Therapeutics, Inc. (-19.33), greater than AbCellera Biologics Inc. (-11.52), greater than Biohaven Ltd. (-2.39), greater than Vera Therapeutics, Inc. (-6.33), greater than Celldex Therapeutics, Inc. (-7.59), greater than Janux Therapeutics, Inc. (-7.73), greater than BioCryst Pharmaceuticals, Inc. (-5.20), greater than Maze Therapeutics, Inc. (-9.34), greater than Harmony Biosciences Holdings, Inc. (13.21),

Build a custom stock screener for Xeris Biopharma Holdings, Inc. (XERS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Xeris Biopharma Holdings, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Xeris Biopharma Holdings, Inc. (XERS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Xeris Biopharma Holdings, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.